Diabetic Ketoacidosis in a Patient with Type 2 Diabetes After Initiation of Sodium-Glucose Cotransporter 2 Inhibitor Treatment

Basic and Clinical Pharmacology and Toxicology

Volumn 118, Issue 2, 2016, Pages 168-170

  Storgaard, Heidi ^a   Bagger, Jonatan I ^a   Knop, Filip K ^a,b   Vilsbøll, Tina ^a   Rungby, Jørgen ^a,c  

^a UNIVERSITY OF COPENHAGEN   (Denmark)

^b UNIVERSITY OF COPENHAGEN   (Denmark)

^c AARHUS UNIVERSITY   (Denmark)

Author keywords

[No Author keywords available]

Indexed keywords

DAPAGLIFLOZIN; GLUCOSE; INSULIN; INSULIN GLARGINE; LIRAGLUTIDE; METFORMIN; SODIUM CHLORIDE; SODIUM GLUCOSE COTRANSPORTER 2 INHIBITOR; 2-(3-(4-ETHOXYBENZYL)-4-CHLOROPHENYL)-6-HYDROXYMETHYLTETRAHYDRO-2H-PYRAN-3,4,5-TRIOL; ANTIDIABETIC AGENT; BENZHYDRYL DERIVATIVE; GLUCOSE BLOOD LEVEL; GLUCOSIDE; SODIUM GLUCOSE COTRANSPORTER 2;

ADD ON THERAPY; ADULT; ARTICLE; CASE REPORT; CELL FUNCTION; DEHYDRATION; DIABETIC KETOACIDOSIS; DISEASE SEVERITY; DIZZINESS; DRUG DOSE INCREASE; DRUG DOSE REDUCTION; GLYCEMIC CONTROL; HOSPITAL ADMISSION; HOSPITAL DISCHARGE; HUMAN; HYPERGLYCEMIA; HYPERTENSION; KETONURIA; LACTIC ACIDOSIS; MALE; METABOLIC ACIDOSIS; NAUSEA; NON INSULIN DEPENDENT DIABETES MELLITUS; OBESITY; PANCREAS ISLET BETA CELL; PRIORITY JOURNAL; TACHYCARDIA; TREATMENT RESPONSE; ANALYSIS; ANTAGONISTS AND INHIBITORS; BLOOD; COMPLICATION; DIABETES MELLITUS, TYPE 2; DRUG EFFECTS; GLUCOSE BLOOD LEVEL; KIDNEY PROXIMAL TUBULE; MEDICATION THERAPY MANAGEMENT; METABOLISM; PATHOPHYSIOLOGY; TREATMENT OUTCOME;

ADULT; BENZHYDRYL COMPOUNDS; BLOOD GLUCOSE; DIABETES MELLITUS, TYPE 2; DIABETIC KETOACIDOSIS; GLUCOSIDES; HUMANS; HYPOGLYCEMIC AGENTS; INSULIN; KIDNEY TUBULES, PROXIMAL; MALE; MEDICATION THERAPY MANAGEMENT; OBESITY; SODIUM-GLUCOSE TRANSPORTER 2; TREATMENT OUTCOME;

EID: 84983185849     PISSN: 17427835     EISSN: 17427843     Source Type: Journal    
DOI: 10.1111/bcpt.12457     Document Type: Article

References (15)

1. Bakris GL, Fonseca VA, Sharma K, Wright EM. Renal sodium-glucose transport: role in diabetes mellitus and potential clinical implications. Kidney Int 2009;75:1272-7.
2. Ptaszynska A, Hardy E, Johnsson E, Parikh S, List J. Effects of dapagliflozin on cardiovascular risk factors. Postgrad Med 2013;125:181-9.
3. Hasan FM, Alsahli M, Gerich JE. SGLT2 inhibitors in the treatment of type 2 diabetes. Diabetes Res Clin Pract 2014;104:297-322.
4. Whalen K, Miller S, Onge ES. The role of sodium-glucose co-transporter 2 inhibitors in the treatment of type 2 diabetes. Clin Ther [Internet]. http://www.sciencedirect.com/science/article/pii/S0149291815001411 (last accessed on 13 June 2015).
5. Research C for DE and Drug Safety and Availability - FDA Drug Safety Communication. FDA warns that SGLT2 inhibitors for diabetes may result in a serious condition of too much acid in the blood [Internet]. http://www.fda.gov/Drugs/DrugSafety/ucm446845.htm (last accessed on 13 June 2015).
6. Gibb FW, Teoh WL, Graham J, Lockmann A. Previous diabetic ketoacidosis is associated with a significant risk of death in the following 5 years. Diabetes 2015;64:273 (abstract).
7. Cox K, Cocchi MN, Salciccioli JD, Carney E, Howell M, Donnino MW. Prevalence and significance of lactic acidosis in diabetic ketoacidosis. J Crit Care 2012;27:132-7.
8. Kaku K, Watada H, Iwamoto Y, Utsunomiya K, Terauchi Y, Tobe K et al. Efficacy and safety of monotherapy with the novel sodium/glucose cotransporter-2 inhibitor tofogliflozin in Japanese patients with type 2 diabetes mellitus: a combined Phase 2 and 3 randomized, placebo-controlled, double-blind, parallel-group comparative study. Cardiovasc Diabetol 2014;13:65.
9. Ferrannini E, Muscelli E, Frascerra S, Baldi S, Mari A, Heise T et al. Metabolic response to sodium-glucose cotransporter 2 inhibition in type 2 diabetic patients. J Clin Invest 2014;124:499-508.
10. Merovci A, Solis-Herrera C, Daniele G, Eldor R, Fiorentino TV, Tripathy D et al. Dapagliflozin improves muscle insulin sensitivity but enhances endogenous glucose production. J Clin Invest 2014;124:509-14.
11. Kalra S, Gupta Y, Patil S. Sodium-glucose cotransporter-2 inhibition and the insulin: glucagon ratio: unexplored dimensions. Indian J Endocrinol Metab 2015;19:426-9.
12. Rui L. Energy metabolism in the liver. Compr Physiol 2014;4:177-97.
13. Bonner C, Kerr-Conte J, Gmyr V, Queniat G, Moerman E, Thévenet J et al. Inhibition of the glucose transporter SGLT2 with dapagliflozin in pancreatic alpha cells triggers glucagon secretion. Nat Med 2015;21:512-7.
14. Peters AL, Buschur EO, Buse JB, Cohan P, Diner JC, Hirsch IB. Euglycemic diabetic ketoacidosis: a potential complication of treatment with sodium-glucose cotransporter 2 inhibition. Diabetes Care 2005;38:1687-93. doi: 10.2337/dc15-0843.
15. http://www.fda.gov/drugs/drugsafety/ucm446845.htm and http://www.ema.europa.eu/ema/index.jsp?curl=pages/medicines/human/referrals/SGLT2_inhibitors/human_referral_prac_000052.jsp&mid=WC0b01ac05805c516f.